Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2( 1H)-on es (TIBO) analogues. 1999

H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
Janssen Research Foundation, Spring House, PA 19477, USA.

4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)-ones (TIBO), 1, have been shown to significantly inhibit HIV-1 replication, as reported in detail in our prior publications. Since our earlier reports, we have modified the TIBO structures 1 by removing the 5-membered ring of 1, generating 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-ones (TBO), 4, a bicyclic series of compounds. Although compounds 4 possess modest activity when compared to TIBO analogues 1, they clearly demonstrated significant anti-HIV-1 activity.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001570 Benzodiazepinones
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
March 2005, Journal of medicinal chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
June 2017, Bioorganic chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
February 1965, The Journal of organic chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
February 2008, Journal of computer-aided molecular design,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
January 2000, Molecular diversity,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
May 1964, Journal of medicinal chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
February 1991, Proceedings of the National Academy of Sciences of the United States of America,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
May 2008, The Journal of organic chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
May 2007, Bioorganic & medicinal chemistry,
H J Breslin, and M J Kukla, and T Kromis, and H Cullis, and F De Knaep, and R Pauwels, and K Andries, and E De Clercq, and M A Janssen, and P A Janssen
November 2008, Journal of molecular modeling,
Copied contents to your clipboard!